olivLaw · US equity research
Cardio Diagnostics Holdings, Inc. CDIO
In Vitro & In Vivo Diagnostic Substances · SIC 2835 · Vertical: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Cardio Diagnostics Holdings develops and sells clinical blood tests for cardiovascular disease, built on epigenetics and an AI platform called the Multi-Omics Engine. The company is still at an early stage, with very small revenue and continuing losses, and its expansion depends largely on winning payer reimbursement, a process that can take years.
At the close of 04 Nov 2026, Cardio Diagnostics Holdings, Inc. (CDIO) stock was 1.65 USD (+2.81% on the day), with market capitalisation 4.9 m USD, beta 2.09, 52-week range 1.05–6.55 USD. Latest reported quarter (Q2 2026): revenue of 5.4 k USD (−28.3% YoY), net income of -1.5 m USD, diluted EPS -0.51 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 41.1
- weak (30–45)
- Bollinger (20, 2)
- 1.59 – 1.85
- in the lower half of the band · %B 0.23 · band width 15.5%
- SMA 50 / 200
- 1.85 / 2.07
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.06 / -0.06
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −20.1% | −1.1% | −19.0 pp | — |
| 3 months | −6.0% | −0.5% | −5.5 pp | — |
| 6 months | −9.6% | +4.4% | −14.0 pp | — |
| Year to date | −39.3% | +12.3% | −51.6 pp | — |
| 1 year | −54.6% | +13.5% | −68.1 pp | −21.1% |
| 3 years | −85.3% | +76.4% | −161.8 pp | −44.4% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.6 k | 4.5 k | 940 | 7.5 k | 2.9 k | 3.6 k | 2.7 k | 5.4 k |
| Research & development | 5.2 k | 204.6 k | 118.8 k | 178.5 k | 189.0 k | 286.9 k | 129.8 k | 162.9 k |
| SG&A | 1.4 m | — | — | 1.7 m | 1.7 m | — | — | — |
| Operating income | -1.4 m | -1.5 m | -1.6 m | -1.7 m | -1.7 m | -1.5 m | -1.8 m | -1.5 m |
| Depreciation & amortisation | 4.8 k | 5.3 k | 45.4 k | 8.5 k | — | — | 5.5 k | 5.6 k |
| Interest expense | 3.9 k | 3.1 k | 4.7 k | 4.7 k | 3.1 k | 2.3 k | 3.4 k | 3.4 k |
| Pre-tax income | -1.4 m | -1.5 m | -1.6 m | -1.7 m | -1.7 m | -1.5 m | -1.8 m | -1.5 m |
| Net income | -1.4 m | -1.5 m | -1.6 m | -1.7 m | -1.7 m | -1.5 m | -1.8 m | -1.5 m |
| Diluted EPS | -1.73 | -1.16 ≈ | -0.97 | -0.97 | -0.98 | -0.80 ≈ | -0.63 | -0.51 |
| Operating cash flow | -1.2 m ≈ | -1.4 m | -1.4 m | -1.6 m ≈ | -1.4 m ≈ | -1.4 m | -1.6 m | -1.3 m ≈ |
| Capex | 23.2 k ≈ | 3.6 k | 5.8 k | 18.7 k ≈ | 162.8 k ≈ | 0 | 1.8 k | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 901 | 950 | 17.1 k | 34.9 k | 14.8 k |
| Revenue YoY | unavailable | +5.4% | +1,696.3% | +104.5% | −57.5% |
| Net income | -620.4 k | -4.7 m | -8.4 m | -8.4 m | -6.5 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -0.53 | -1.51 | -0.66 | -9.35 | -3.71 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -68,862.2% | -490,630.0% | -49,087.8% | -24,028.2% | -43,832.5% |
| Free cash flow | unavailable | unavailable | -6.2 m | -5.2 m | -5.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 0 USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 7.0 m USD
- Total assets
- 7.8 m USD
- Debt / equity
- unavailable
- Current ratio
- 9.79x
- ROE
- -78.6%
- ROA
- -70.7%
- FCF margin
- -39,893.1%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Revenue | 901 | 950 | 17.1 k | 34.9 k | 14.8 k | SEC (XBRL)· 13 Mar 2026verified |
| Research & development | 31.5 k | 40.4 k | 145.2 k | 228.0 k | 641.2 k | SEC (XBRL)· 13 Mar 2026verified |
| Operating income | -620.4 k | -4.5 m | -7.2 m | -8.4 m | -6.5 m | SEC (XBRL)· 13 Mar 2026verified |
| Depreciation & amortisation | 16.0 k | 16.0 k | 19.2 k | 19.7 k | 65.2 k | SEC (XBRL)· 13 Mar 2026verified |
| EBITDA | -604.4 k ≈ | -4.5 m ≈ | -7.2 m ≈ | -8.3 m ≈ | -6.4 m ≈ | SEC (XBRL)· 13 Mar 2026derived |
| Interest expense | — | — | 6.7 m | 18.6 k | 14.8 k | SEC (XBRL)· 13 Mar 2026verified |
| Pre-tax income | -620.4 k | -4.7 m | -8.4 m | -8.4 m | -6.5 m | SEC (XBRL)· 13 Mar 2026verified |
| Income tax | 0 | 0 | — | — | — | SEC (XBRL)· 31 Mar 2023verified |
| Net income | -620.4 k | -4.7 m | -8.4 m | -8.4 m | -6.5 m | SEC (XBRL)· 13 Mar 2026verified |
| Diluted EPS | -0.53 | -1.51 | -0.66 | -9.35 | -3.71 | SEC (XBRL)· 13 Mar 2026verified |
| Weighted average diluted shares | 1.2 m | 3.1 m | 12.7 m | 896.4 k | 1.8 m | SEC (XBRL)· 13 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Cash | 0 | 0 | 0 | 0 | 0 | SEC (XBRL)· 13 Mar 2026verified |
| Receivables | 901 | 0 | 5.0 k | 18.6 k | 8.1 k | SEC (XBRL)· 13 Mar 2026verified |
| Current assets | 803.5 k | 5.9 m | 2.8 m | 8.8 m | 5.9 m | SEC (XBRL)· 13 Mar 2026verified |
| Property, plant & equipment, net | — | 0 | 571.9 k | 672.9 k | 700.1 k | SEC (XBRL)· 13 Mar 2026verified |
| Intangibles (excl. goodwill) | 53.3 k | 37.3 k | 21.3 k | 5.3 k | — | SEC (XBRL)· 20 Mar 2025verified |
| Total assets | 1.1 m | 6.2 m | 4.5 m | 10.6 m | 7.8 m | SEC (XBRL)· 13 Mar 2026verified |
| Accounts payable | 33.9 k | 1.1 m | 243.2 k | 87.7 k | 97.4 k | SEC (XBRL)· 13 Mar 2026verified |
| Current liabilities | 124.4 k | 1.9 m | 841.1 k | 631.7 k | 604.8 k | SEC (XBRL)· 13 Mar 2026verified |
| Total liabilities | 33.9 k | 1.9 m | 1.5 m | 1.1 m | 793.1 k | SEC (XBRL)· 13 Mar 2026verified |
| Equity | 1.1 m † | 4.3 m † | 3.0 m † | 9.6 m † | 7.0 m † | SEC (XBRL)· 13 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Operating cash flow | -585.3 k | -5.1 m | -5.7 m | -5.0 m | -5.7 m | SEC (XBRL)· 13 Mar 2026verified |
| Capex | — | — | 575.7 k | 214.8 k | 187.3 k | SEC (XBRL)· 13 Mar 2026verified |
| Free cash flow | — | — | -6.2 m ≈ | -5.2 m ≈ | -5.9 m ≈ | SEC (XBRL)· 13 Mar 2026derived |
| Investing cash flow | -364.0 k | -368.0 k | -794.3 k | -404.2 k | -419.3 k | SEC (XBRL)· 13 Mar 2026verified |
| Financing cash flow | 1.2 m | 9.1 m | 3.6 m | 11.9 m | 3.4 m | SEC (XBRL)· 13 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 4.9 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -44,771.8% | 13 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 149.9% | 100 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -525.1x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 17.1x | 100 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -119.6% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial13/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Cardio Diagnostics Holdings, Inc. (CDIO). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 14.8 k USD in 2025; YoY growth -57.5%; net margin -44,771.8%; ROE -75.4%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 149.9%
- Current ratio: 17.1x
What contradicts it
- Net margin: -44,771.8%
- Interest coverage: -525.1x
- FCF yield: -119.6%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
In Vitro & In Vivo Diagnostic Substances (SIC 2835) · same industry (4-digit SIC) · compared with 17 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IDXXIdexx Laboratories Inc | 55.0 bn | 47.1 | 68.9% | 25.4% | +10.4% | −7% / +50% |
| LNTHLantheus Holdings, Inc. | 6.6 bn | 24.5 | 22.2% | 17.7% | +0.5% | +72% / +41% |
| NEOGNeogen Corporation | 2.7 bn | — | -2.7% | -6.3% | −2.7% | +108% / −27% |
| TRIBTrinity Biotech PLC | 2.4 bn | — | — | -51.6% | +8.3% | −80% / −91% |
| CLDXCelldex Therapeutics, Inc. | 2.4 bn | — | -43.9% | -190,220.9% | −78.0% | +11% / −1% |
| NTLAIntellia Therapeutics, Inc. | 1.7 bn | — | -6,424.8% | -672.2% | +16.9% | +37% / −58% |
| QDELQuidelortho Corp | 984.6 m | — | -19.3% | -14.2% | −1.9% | −48% / −79% |
| ACHVAchieve Life Sciences, Inc. | 718.3 m | — | -845.0% | — | unavailable | +43% / +21% |
| MYGNMyriad Genetics, Inc. | 575.8 m | — | -32.5% | -14.0% | −1.6% | −21% / −68% |
| TKNOAlpha Teknova, Inc. | 395.7 m | — | -24.2% | -38.4% | +7.4% | +57% / +261% |
| ICCCImmuCell Corporation | 94.2 m | 138.2 | 2.6% | 2.6% | +4.3% | +114% / +128% |
| IMDXInsight Molecular Diagnostics Inc. | 86.7 m | — | — | -2,955.6% | +115.6% | −57% / −30% |
| BMRABiomerica, Inc. | 8.0 m | — | -113.8% | -115.5% | −16.2% | −27% / −77% |
| CDIOCardio Diagnostics Holdings, Inc. | 4.9 m | — | -75.4% | -44,771.8% | −57.5% | −55% / −85% |
| QCLSQ/C Technologies, Inc. | 3.2 m | — | -155.0% | — | −5.3% | −89% / −100% |
| VNRXVolitionRx Limited | 2.8 m | — | — | -1,043.1% | +40.0% | −97% / −99% |
| VRAXVirax Biolabs Group Ltd | 695.1 k | — | -109.6% | -95,739.2% | −96.0% | −88% / −98% |
| NNNNAnbio Biotechnology | — | 25.0 | 27.0% | 74.1% | +5.6% | −84% / unavailable |
1- and 3-year price returns: for CDIO from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Cardio Diagnostics Holdings develops and sells clinical blood tests for cardiovascular disease, built on epigenetics and an AI platform called the Multi-Omics Engine. The company is still at an early stage, with very small revenue and continuing losses, and its expansion depends largely on winning payer reimbursement, a process that can take years 12.
SWOT
Strengths
- A portfolio of clinical tests with CPT PLA codes and a set CMS payment rate.
- A proprietary AI platform built over several years of research.
- An in-house CLIA laboratory that reduces reliance on third parties.
Weaknesses
- Very small revenue and continuing net losses over the past two years.
- Funding that depends on equity sales under the at-the-market program.
- Long sales and partnership cycles, sometimes exceeding two years.
Opportunities
- Wider reimbursement from Medicare and other commercial payers.
- Development of new tests for stroke, heart failure and diabetes.
- International expansion, starting with India.
Threats
- A slow pace of payer coverage could limit growth.
- Dilution of shareholders from equity-based financing.
- Economic pressure could slow prevention budgets.
Risks
- Negligible revenuehigh
The company has reported very small revenue and has not yet reached profitability, and it may never do so 1.
- Need for additional capitalhigh
The company relies on at-the-market equity sales, and if it cannot raise funds it could scale back operations 1.
- Uncertain reimbursementmedium
Without broad payer coverage, test volume could remain limited, and the process may take years 12.
- Dilutionmedium
Share issuances may reduce the stake of existing shareholders and may carry liquidation preferences 1.
- Regulatory changelow
Although the LDT rule was rescinded, a future FDA framework or other regulation could change operating conditions 1.
Investment thesis
What would need to be true (bull case)
- If payer coverage widens, the existing tests could generate much higher volume without a proportional rise in costs.
- The in-house CLIA laboratory and the first covered commercial payer could strengthen the company's position in the US.
- International expansion and new tests could diversify revenue sources if execution succeeds.
What would break the thesis
- Revenue is close to nonexistent, and continuing losses could use up available capital before sales grow.
- Reliance on equity financing could heavily dilute existing shareholders.
- Long reimbursement cycles could delay meaningful revenue by years.
What to watch
- Revenue trend and expansion of commercial payer coverageQ3 2026
- New York license approval and test volume2026
- Progress on Medicare coveragenext 10-K
- India implementation and regular shipments2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Cardio was formed to develop and commercialize products for major types of cardiovascular disease and associated comorbidities, including coronary heart disease, stroke, heart failure and diabetes 1. Its first tests are Epi+Gen CHD, launched in 2021, and PrecisionCHD, launched in March 2023, both categorized as laboratory-developed tests 1. Revenue was nominal: $14,825 in 2025, compared with $34,890 in 2024, mainly because a heart attack prevention testing initiative with Family Medicine Specialists concluded 1. By June 2026 the company had begun testing patient samples in its new high complexity CLIA laboratory, which could reduce cost of goods sold if volume grows 2.
Segments
Clinical blood tests
Epi+Gen CHD and PrecisionCHD are epigenetic-genetic tests for coronary heart disease risk assessment and detection. The company has secured CPT PLA codes and CMS gapfill payment rates of $854 per test 1. The first commercial payer to cover them is a California independent physician association, with coverage from May 2026 2.
Market context
The company cites a global cardiovascular diagnostic testing market estimated at $8.47 billion in 2022, projected to grow to $12.41 billion by 2027 at a CAGR of 7.94% 1. Cardiovascular disease costs in the United States were $555 billion in 2016 and are projected to exceed $1 trillion by 2035 1. If demand for early prevention keeps growing, the market could become more receptive to products like Cardio's 1.
Trends
- Aging populationtailwind
The number of Americans aged 65 and over is projected to grow substantially by 2060, which could increase demand for cardiovascular diagnostics 1.
- Shift to value-based caretailwind
Quality-based payment models may encourage providers to prevent costly events, which could favor early testing 1.
- FDA withdrawal from LDT regulationmixed
In September 2025 the FDA rescinded its May 2024 rule on laboratory-developed tests, returning oversight to CLIA 1. This reduces regulatory uncertainty but does not remove the need for reimbursement.
- Long reimbursement cyclesheadwind
Securing coverage from Medicare and commercial payers can take years, which limits meaningful revenue in the meantime 12. If the process accelerates, the impact could turn positive.
Competitive position
The provided sources do not name any US-listed competitors, so the profile cannot identify competing companies with certainty. The company differentiates itself through its epigenetic evidence base and by combining clinical tests with data products for employers 1. Direct competition could come from laboratories offering similar cardiovascular tests, though these are not described in the source documents.
- Cardiovascular diagnostic laboratories (not named in sources)
The source documents do not name specific competitors; this is a general category.
- Genetic and epigenetic testing providers
Not named in the provided sources; they could compete for the same payers and providers.
- Channel partners and reimbursement gatekeepers
Not direct competitors, but they influence market access.
- Employer risk analytics platforms
Not named in the sources; they could compete with HeartRisk for benefit budgets.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Doi copii au fost găsiți în stop cardio-respirator la Tălmaciu, Sibiu, după ce o saltea a luat foc într-o locuințăLibertatea.ro · 28 Oct 2026 · RO
- Doi copii de 2 și 4 ani au murit după ce au fost găsiți în stop cardio-respirator într-o locuință din Sibiu. Prima ipoteză, o saltea care a luat focAdevărul · 28 Oct 2026 · RO
- Sibiu: Doi copii de 2 și 4 ani, găsiți în stop cardio-respirator într-o locuință din Tălmaciu. Medicii încearcă să îi resuscitezeMediafax · 28 Oct 2026 · RO
- 5 great cardio workouts you can do at homeMedical Xpress · 23 Oct 2026 · EN
- Doing a short cardio session after weight training probably won't boost your gains—here's whyMedical Xpress · 14 Oct 2026 · EN
- De ce Gen Z înlocuiește antrenamentele cardio cu cele de forță - BBCSurge — Google News · 03 Oct 2026 · RO
- STAT+: Key data on a new class of cardio drugs are comingSTAT News · 26 Aug 2026 · EN
- Motociclist de 46 de ani, mort într-un accident în Pasul Mestecăniș. Bărbatul a intrat în stop cardio-respirator în drum spre spitalAdevărul · 15 Aug 2026 · RO
- Patru angajaţi ai Penitenciarului Giurgiu au fost reţinuţi după ce un deţinut bătut a intrat în stop cardio-respiratorDigi24 · 04 Aug 2026 · RO
- Patru bărbaţi reţinuţi în dosarul de purtare abuzivă de la Penitenciarul Giurgiu / Ar fi lovit un deținut până a intrat în stop cardio-respiratorG4Media · 04 Aug 2026 · RO
- Percheziții și audieri după ce un deținut al Penitenciarului Giurgiu a fost bătut și a intrat în stop cardio-respirator. Mai mulți angajați, vizați de anchetăAdevărul · 03 Aug 2026 · RO
- Grav accident în Cluj. Două fetițe de 10 ani, găsite în stop cardio-respirator, au fost resuscitate. O femeie și un alt copil, descarcerațiAdevărul · 31 Jul 2026 · RO
- TOP 5 beneficii ale antrenamentelor care combină cardio și coordonarea – by World ClassSpotMedia.ro · 16 Jul 2026 · RO
- Un turist din Bucureşti a decedat pe munte, în apropierea Vârfului Caraiman, în urma unui stop cardio-respiratorG4Media · 14 Jul 2026 · RO
- Accident grav cu 9 oameni pe DN1, în Brașov: un copil și o femeie în stop cardio-respirator după ce 3 mașini s-au lovitLibertatea.ro · 30 May 2026 · RO
SEC filings
- Current report18 Sept 2026Shareholder vote · Financial statements and exhibits
- Current report20 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report07 Aug 2026
- Proxy statement05 Aug 2026
- Quarterly report15 May 2026
- Annual report13 Mar 2026
- Current report19 Feb 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report12 Nov 2025
- Current report15 Oct 2025Shareholder vote · Financial statements and exhibits
- Proxy statement04 Sept 2025
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Cardio Diagnostics Holdings, Inc. · 13 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Cardio Diagnostics Holdings, Inc. · 07 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.